EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen.

Trial Profile

EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Zotarolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel
  • Indications Stent thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EDUCATE
  • Sponsors Medtronic AVE
  • Most Recent Events

    • 29 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Nov 2012 Planned End Date changed from 1 Nov 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.
    • 12 Apr 2012 Planned end date changed from 1 Dec 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top